arrow
S

Seema Naik

Penn State Cancer Institute
H指数:19
被引数:1,276

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma

一项随机II期研究:皮下注射mosunetuzumab联合polatuzumab vedotin与利妥昔单抗联合polatuzumab vedotin治疗复发或难治性大B细胞淋巴瘤患者的比较研究

2026-07-280
OAAI
Epcoritamab monotherapy as outpatient treatment for patients with relapsed/refractory diffuse large B-cell lymphoma: Interim results from EPCORE NHL-6

Epcoritamab单药治疗门诊患者复发/难治性弥漫大B细胞淋巴瘤:EPCORE NHL-6研究的阶段性结果

2026-05-010
OAAI
Safety and feasibility of intermediate-dose post-transplant cyclophosphamide for graft-versus-host disease prophylaxis

移植后中剂量环磷酰胺在移植物抗宿主病预防中的安全性与可行性

2025-10-130
OA
A prior status of graft-versus-host disease affects donor lymphocyte infusion outcomes in patients with relapsed haematological malignancies after allogeneic stem cell transplantation

移植物抗宿主病的先前状态影响异基因干细胞移植后复发血液系统恶性肿瘤患者接受供者淋巴细胞输注的结局。

2025-06-180
OA
The impact of a personal cancer diagnosis on adolescent and young adult cancer survivors' social connectedness: A qualitative analysis

个人癌症诊断对青少年及青年癌症幸存者社会连接的影响:一项定性分析

2025-01-310
PRE
Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism
2024-12-011
PRE
Real World Evidence of Daratumumab-Based Treatment in AL Amyloidosis

基于达鲁单抗的治疗在AL淀粉样变性中的真实世界证据

BLOOD
IF23.1
2024-11-050
PRE
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
2024-10-110
PRE
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
2023-12-1018
OAAI
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
2023-10-2512
OAAI
CD26lowPD-1+ CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia

CD26lowPD-1 CD8 T细胞终末耗尽并与急性髓系白血病进展相关

2023-06-295
OAAI
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 US cancer centers
2023-04-0512
OA
Donor HLA mismatch promotes full donor T-cell chimerism in the allogeneic stem cell transplant with reduced-intensity conditioning and post-transplant cyclophosphamide GVHD prophylaxis
2022-12-172
PRE
Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation
2022-06-018
OAAI
Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant

异基因造血干细胞移植后环磷酰胺改变免疫特征并导致T细胞重建受损

2022-05-1930
OAAI
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis
2021-07-2027
OA
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
2021-02-0420
OAAI